NeuroWave Systems Inc. to Present at IN3 East Investor Conference in Boston, June 22, 2011

Beachwood, OH, June 14, 2011 -- NeuroWave Systems Inc., the emerging medical device innovator and manufacturer of intelligent brain monitors for clinical applications in Anesthesia, Critical Care, Neurology and Emergency Medicine, today announced that its President, Tatjana Zikov, and its VP and General Counsel - Legal, IP and Business development, Dr. Brian Kolkowski will make a presentation at Elsevier's IN3 East Investor Conference in Boston. NeuroWave has been invited to be a part of the interactive Panel Discussion/Case Study “Making the Pitch: What do Dealmakers Want?” (Wednesday, June 22, 8:05 am, Hyatt Regency Boston).

NeuroWave is looking to close up to $5 million in 2011. The funds would mainly be used to finance sales and marketing efforts to accelerate product sales and market expansion for the CE Marked NeuroSENSE® Monitor with EasyPrepTM disposable electrodes, the next generation brain monitor for safe and accurate anesthesia/sedation and improved outcomes in the OR and ICU. NeuroSENSE is currently being sold in Europe and other worldwide sales are just starting.

Traditional methods for dosing anesthesia or sedation have inherent risks of under- or over-dosing, leading to awareness during surgery, cognitive decline, prolonged recovery, extended stay on ventilator, increased mortality, etc. Every day, more than 100 patients in the US experience awareness during surgery, while one patient dies due to anesthesia overdose. In the ICU, for instance, prolonged ventilation associated with over-sedation costs $16 Billion annually.

Total market opportunity for Anesthesia and Sedation Monitoring is estimated to $3 billion worldwide, while the competition is limited to one company having the bulk of the current market share and having significant performance limitations. Key Opinion Leaders (KOLs) argue that faster, more accurate and more reliable technologies are needed, and they should be transparent and biologically explicable.

"We anticipate a very positive response from investors,” said Ms. Zikov. “The NeuroWave story is very compelling from the investment perspective. NeuroWave has unique technology that has resolved the issues not properly addressed by the competition. We believe our technology fulfills the expectations set by KOLs and makes us uniquely positioned to be a leader in this market.”

About NeuroWave Systems Inc.:
NeuroWave Systems Inc. is focused on developing intelligent brain monitoring devices. The Company's mission is to develop, manufacture, and market monitoring products using advanced signal processing of brain waves (electroencephalogram - EEG) and other biosignals for Neurology, Anesthesia, Critical Care and Emergency Medicine, in order to improve patient outcome and quality of life.